Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose gilteritinib to prevent post-transplant relapse in FLT3-mutated high-risk AML
ChiCTR2400080664Phase 2Not yet recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoint: 2-year cumulative recurrence rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400080664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080664.